A client with a nasogastric tube is prescribed therapy to prevent ulcer development.
Which of the following would be the best option for the drug?

Choice A rationale:

Alkylating agents are cell cycle-specific drugs. They work on cells during various stages of the cell cycle and are classified as cell cycle phase-nonspecific drugs. These drugs form covalent bonds with DNA, preventing DNA replication and transcription. This action disrupts the cell cycle, making them effective against actively dividing cells.

Choice B rationale:

Plant alkaloids are not cell cycle-specific drugs. Plant alkaloids, such as vinblastine and vincristine, are derived from plants and are classified as cell cycle phase-specific drugs. They primarily affect cells during the M phase of the cell cycle by disrupting microtubule formation. While they are effective against rapidly dividing cells, they are not cell cycle-specific.

Choice C rationale:

Antineoplastic antibiotics are not cell cycle-specific drugs. These drugs, such as doxorubicin and daunorubicin, are used in cancer treatment and primarily work by intercalating with DNA and inhibiting topoisomerase enzymes. Their mechanisms of action do not specifically target a particular phase of the cell cycle, making them cell cycle phase-nonspecific.

Choice D rationale:

Retinoids are not cell cycle-specific drugs. Retinoids are derived from vitamin A and have various mechanisms of action, including regulating cell growth and differentiation. They are not classified as cell cycle-specific drugs.

Choice A rationale:

Administering a combination of drugs in TB treatment is not primarily aimed at preventing the incidence of liver dysfunction. The combination therapy's main objective is to address the complex nature of Mycobacterium tuberculosis infections and the potential development of antibiotic resistance.

Choice B rationale:

The nurse should explain that the primary reason for administering a combination of drugs is to slow down bacterial resistance. When TB is treated with a single drug, the bacteria can quickly develop resistance to that drug. Using a combination of drugs with different mechanisms of action makes it more difficult for the bacteria to develop resistance. This is a fundamental principle in the treatment of TB.

Choice C rationale:

Slowing the body's resistance to medication is not a goal in TB treatment. The focus is on preventing the development of resistance in the bacteria, not the body's response to the medication.

Choice D rationale:

While TB treatment aims to prevent the further spread of the disease, the primary reason for using a combination of drugs is to address bacterial resistance. Preventing the spread of TB is an important secondary benefit of effective treatment.